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Abstract
Aims:Neuroferritinopathyor Hereditary Ferritinopathy (HF)is an autosomal dominant movement 
disorder due to mutation in the light chain of the iron storage protein ferritin (FTL).HF is the only A
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late-onset neurodegeneration with brain iron accumulation disorder andstudy of HF offers a 
unique opportunity to understand the role of iron in more common neurodegenerative syndromes. 
Methods:We carried out pathological and biochemical studies of six individuals with the same 
pathogenic FTL mutation.
Results:CNS pathological changes were most prominent in the basal ganglia and cerebellar 
dentate, echoing the normal pattern of brain iron accumulation.Accumulation of ferritin and iron 
was conspicuous in cells with a phenotype suggestingoligodendrocytes, withaccompanying 
neuronal pathology and neuronal loss. Neuronsstill survived however, despite extensive adjacent 
glial iron deposition, suggesting neuronal loss is a downstream event.Typical age-related 
neurodegenerative pathology was not normally present.Uniquely, the extensive aggregates of 
ubiquitinated ferritin identified indicate that abnormal FTLcan aggregate, reflecting 
theintrinsicability of FTL to self-assemble.Ferritin aggregates were seenin neuronal and glial 
nuclei showing parallels with Huntington’s disease. There was no evidence of oxidative stress 
activation nor any significant mitochondrial pathologyin the affected basal ganglia. 
Conclusions:HF shows hallmarks of a protein aggregation disorder, in addition to iron 
accumulation.Degeneration in HF is not accompanied by age-related neurodegenerative pathology 
and the lack of evidence of oxidative stress and mitochondrial damage suggests these are not key 
mediators of neurodegeneration in HF, casting light on other neurodegenerative diseases 
characterised by iron deposition.  
Abbreviations:
FTL – Ferritin Light Chain
FTH – Ferritin Heavy Chain
HF – Hereditary Ferritinopathy
NBIA – Neurodegeneration with Brain Iron Accumulation
NF - Neuroferritinopathy
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Introduction
Abnormal metabolism of iron has been observed extensively in common neurodegenerative 
disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD)(1-3), although it 
remains unclear if this is a secondary effect of neurodegeneration, or whether it directly 
contributes to cell death. For example in PD, the substantia nigrahas been shown to be particularly 
vulnerableto iron mediated damage of dopaminergic neurons(4-6) possibly due to the development 
of reactive oxygen species (ROS)(7), whilst in AD subtle differences in the localisation of iron in 
relation to neurons and the uptake of iron by microglia and astrocytes following cell death suggest 
that iron accumulation may be a secondary phenomenon of cellular injury(3, 8)(forreview see(9)). 
Neuroferritinopathy (NF) or Hereditary Ferritinopathy (HF) is one of several Neurodegeneration 
with Brain Iron Accumulation (NBIA) disorders and occurs commonly due to a frameshift 
mutation in the light-chain of ferritin (FTL), resulting in an elongated C-terminus to the ferritin 
monomer and an altered amino acid sequence(10-12). This change in the ferritin monomer may 
result in an increased propensity of iron to leak from ferritin oligomers, and associates with iron 
accumulation within the brain(10, 13, 14). 
Unlike other NBIA disorders, HF is a late onset autosomal dominant disorder, and one of the only 
disorders in which the primary metabolic defect is within an iron metabolism protein, rather than a 
consequence of metabolic dysfunction not directly associated with iron metabolism(15, 16). In 
addition, the spatial deposition of iron in neuroferritinopathy appears similar to the iron deposition 
seen in the normal aging brain(2, 17). Therefore, HF could be considered to exhibit the closest 
model of ‘exaggerated’ iron accumulation found in normal aging, and thus the best in vivo 
opportunity to understand the mechanism by which iron deposition may contribute to neuronal 
death and neuropathology seen in other NBIA.
Herewe confirm that in HF; (1)iron deposition follows the normal regionalaccumulation of iron in 
the aging brain, (2) occurs diffusely throughout the brain, particularlyin gliabut also neurons, (3) 
does not cause significant ROS production or mitochondrial DNA mutations, (4) 
polyubiquitination of ferritin occurs, and (5)that intracellular and intranuclear aggregates of FTL 
develop in a manner analogous to CAG repeat disorders.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Materials and Methods
Post-mortem brain histology and iron histochemistry
Fixed and frozen post-mortem brain tissue from sixindividuals were utilised within this study. All 
procedures were approved by the National Health Service Local Research Ethics Committee and 
appropriate informed consent was obtained from donors or next of kin for tissue donation. 
Neuropathology of paraffin embedded tissue sections (10m) usedroutine haematoxylin and eosin 
and luxol fast blue/cresyl fast violet to demonstrate myelin and neurons. Iron histochemistry used 
the DAB intensification procedure applied to Perls’ or Turnbull’s Prussian Blue reaction (2, 18, 
19)and was used to demonstrate ferric (Fe3+) or endogenous ferrous (Fe2+) forms of iron 
deposition (Supplementary Methods). 
Immunohistochemistry
Tissue sectionswere stained with antibodies to GFAP, ferritin, amyloid-beta (4G8), CD68, HLA-
DR/DP/DQ, a phosphorylated epitope of tau (AT8), heavy neurofilament, ubiquitin, or alpha-
synuclein (KM51) (Supplementary Methods).
Haem Oxygenase-1 (HO-1) immunohistochemical detection was performed on 10 μm paraffin 
sections of the following brain areas: frontal cortex, motor cortex, cerebellum including dentate 
nucleus, brainstem, anterior basal ganglia, basal ganglia at the globus pallidus, thalamus, 
hippocampal CA1 and CA2 regions, dentate gyrus, entorhinal cortex, and substantia 
nigra(Supplementary Methods). 
Brain protein homogenate preparation, fractionation and western blot
Frozen unfixed tissue blocks of the frontal cortex or lateral cerebellum were available from 4 cases 
with HF (Cases II, III, IV and VI). Tissue was homogenized in an extraction buffer consisting of 
0.2M triethylammonium bicarbonate (pH8.0, TEAB, Sigma) and protease inhibitor cocktail 
(Roche), following which samples were prepared for western blotting or fractionated into 
detergent soluble and insoluble fractions (Supplementary Methods).  
Native PAGE
Digitonin or Triton X-100 soluble tissue fractions were subjected to native PAGE analysis using 
the NativePAGENovex Bis-Tris system (Life Technologies) components. Following A
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electrophoresis, western blot was performed with several modifications to the standard protocol 
(details in Supplementary Methods). 
Detection of protein carbonyls and Cathepsin D/E activity
Oxidative modifications in proteins were detected using the OxyBlot protein oxidation detection 
kit (Millipore). Cathepsin D and E activities in frontal cortex samples weremeasured using a 
kinetic assaydescribed previously(20)(Supplementary Methods).
Inductively Coupled Plasma Emission Mass Spectrometry (ICPMS)
Metal levels were determined in frozen tissues from cases II, III, and IV using ICPMS utilising a 
standard additions approach with multi-element standards. Tissue samples were wet digested with 
nitric acid and analysed using a Thermo X Series 2 mass spectrometer (Supplementary Methods).
Mitochondrial DNA (mtDNA) single nucleotide variant analysis
Frozen unfixed post-mortem tissue blocks containing the frontal cortex, motor cortex, cerebellum, 
globus pallidus, putamen and thalamus were dissected and DNA was extracted(Supplementary 
Methods). DNA was analysed for heteroplasmic and homoplasmic mtDNA point mutations using 
high-depth amplicon based sequencing(21).The data was analysed using an in-house developed 
bioinformatic pipeline (21). The minimal coverage at a minimal read depth 1500× was 96.6% 
(average 99.2%). The minimal variant frequency was considered to be 1%.  
Statistical analysis
Statistical analysis was performed in IBM SPSS 22. Graphs were generated in Microsoft Excel 
2010 or GrapPad Prism version 5.04. Data were analysed for normality using Shapiro-Wilk test. 
Statistical significance was determined based on parametric (independent samples test) or non-
parametric (Mann-Whitney test) methods and a significant difference was considered when p ≤ 
0.05.  
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Results
Clinical presentation of HF cases
All patients of this extended pedigree carried the previously reported 460InsA mutation in exon 4 
of FTL that elongates the C-terminal region of the FTL protein(10).Patients showed symptoms 
typical of the detailed clinical descriptions of HF presentation and progression provided 
previously(22). Gender of individuals has been masked where possible for the purposes of 
maintaining anonymity for families in a rare disorder.
Case I: A 51-year-oldindividual and a carrier of the 460InsA mutation due to detection in a first-
degree relative. They died from unrelated causes prior to the onset of major neurological 
symptoms. 
Case II: A 53-year-oldwhopresented to neurology following the diagnosis of HF in first-degree 
relative. A CT scan at presentation showed no abnormality within the basal ganglia, and they were 
asymptomatic at initial review. Five years later (aged 58), they showeda symmetrical but mild 
dyskinesia of the upper limbs, together with an orofacial dyskinesia characterised by pursing of 
the lips. On examination they also exhibited occasional choreiform movements of the upper 
limbs,weremildly ataxic, and had a cerebellar dysarthria. Informal testing of memory and intellect 
was deemed to be normal, although affect was slightly disinhibited.Aged 62, an MRI brain scan 
showed increased T2 signal in the basal ganglia along with mild generalised cerebral and 
cerebellar atrophy. Over the next three years neurological symptoms progressed, with a 
deteriorationof hyperkinetic upper limb movements and progressive memory impairment. Aged 
65, a repeat MRI and CT examination again showed bilateral abnormalities in the basal ganglia 
indicating increased iron signal and now cavitation. Aged 69,they were immobile, fully dependent 
for all activities of daily living and aphasic. Death was due to aspiration pneumonia eleven years 
after the onset of symptoms.
Case III: A 58-year-oldwho presented with a 5-year history of involuntary movements of the left 
foot, together with a 2-year history of involuntary movements of the left upper limb. Over the next 
6 months,they also developed a progressive dysphagia for solids and liquids and progressive 
dysphonia. Neurological examination revealed an orofacial dyskinesia, and choreiform 
movementsof the left arm only. One parent had been givena clinical diagnosis of Huntington’s 
disease, though never received a molecular diagnosis. A CT scan of the brain showed bilateral 
cavitation within the basal ganglia with a normal caudate nucleus.  An MRI scan showed changes 
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associated with iron deposition within the basal ganglia. The patient died 3 years after 
presentation.
Case IV: A 41-year-old presented with a4-year history of a mild spastic paraparesis. Five years 
later these pyramidal symptoms had also developed symmetrically in the upper limbs, and lower 
limb pyramidal features had also advanced, although the plantars remained downgoing. In 
addition, dystonic movements had also developed in the left upper limb. Neuropsychiatric testing 
aged 46 showed reduced verbal memory and processing speed with dysarthric speech consistent 
with a cerebellar dysarthria. CT imaging of their brain showed discrete lesions in both putamen 
with MRI imaging showing high T2 signal in the putamen and globus pallidus consistent with iron 
deposition. Aged 47, pyramidal tract features, cerebellar ataxia, and memorywere noted to have 
deteriorated further. At age 50, the dystonic gait was particularly troublesome, and symptoms 
slowly deteriorated until they died aged 55.
Case V: A 47-year-old who presented with a slowly progressive left sided hemiparesis. There was 
gradual deterioration over thesubsequent 10 years, with progressive weakness and 
spasticitypredominantly affecting the left side. Speech gradually deteriorated from their mid-50s, 
and at 61yrs, dysphagia and dysphonia were prominent. By 61,they had also developed a mild 
deficit in short term memory on formal cognitive testing, together withboth lower and upper limb 
dystonia. There was no ataxia. An MRI scan aged 61 showed cystic cavitation of the putamen and 
globus pallidus bilaterally. There was continued deterioration over the next 5 yearswith the patient 
eventually unable to walk, requiringinstitutionalcare including enteral feeding. They died age 66 
of bronchopneumonia.
Case VI: A 50-year-old whopresented with involuntary choreiform movements of their right hand. 
Over the next 10 years, the upper limb chorea became bilateral, and by the age of 60 they had also 
developed significant dysphagia and dysarthria. Aged 62 they had a profound gait disorder, though 
it is unclear whether this was due to dystonia or ataxia. MRI at age 75 showed bilateral 
symmetrical lesions through the globus pallidus, putamen, caudate and subthalamic nucleus. By 
age 75 they were wheelchair bound, aphasic, severely dysphagic and a rapid decline in cognition 
was noted, though this was uncharacterized clinically. They died aged 76 of 
bronchopneumonia.Details of this individual have been reported previously(23). 
LiverPathology
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Haematoxylin and eosin stained sections of post-mortem liver(cases I, III, and VI) showed 5-20 
micron diameter roughly spherical eosinophilic inclusions with a pale halo in hepatocytes, 
typically within nuclei, and diffusely distributed smaller inclusionsthroughout the cytoplasm as 
observed previously (10, 11). Staining with Perls’ showed the presence of iron within the 
inclusions and cell nuclei stained for ferritin (Figure 1). Histology of ventricular heart tissue 
showed low level intranuclear staining for ferritin although Perls’ stain did not show the presence 
of significant iron. Sections of skin tissue showed diffuse staining with Perls’ iron and intranuclear 
staining of cells within the basal epidermis and within glandular cellswith FTL IHC although 
inclusions were not observed (Figure 1).
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Macroscopic CNS Pathology
Pathology focussed on the basal ganglia (Figure 2)and was consistent with neuroimaging findings 
in HF(22, 24, 25) (see Supplementary Figure 1) witha gradation of pathology from mild in case I 
to severe in cases III, V and VI. In all cases, a brown discoloration of the basal gangliawas 
observed, particularly the remains of the globus pallidus and putamen, but also in the substantia 
nigra pars reticulata, red nucleus, cerebellar dentate nucleus, and to a lesser extent the subthalamic 
nucleus and caudate. Cystic lesions were observed in the internal medullary lamina between the 
globus pallidus and putamen in case I, which was enlarged in case II, and marked in cases III-
VIwith cavitation extendingthroughout the external globus pallidus and within the putamen, with 
little pallidal or putaminal tissue remaining (Figure 2). In case III, cavitation in the dentate nucleus 
and substantia nigra was also noted. The cerebellum showed no major atrophy and the brainstem 
appeared normal. In the cerebral hemispheres there was some cortical deep white matter pallor in 
case III and VI.
Microscopic pathology
Basal Ganglia
Microscopic pathology followed macroscopic pathology, being least severe in case I, intermediate 
in case II, and most severe in cases III-VI (Supplementary Figure 2). On microscopic examination, 
abundant eosinophilic, roughly sphericalinclusions up to 50m in diameter were observed in the 
remaining putamen and globus pallidus surrounding the cavity(Figure 3). Histochemistry 
showediron predominantly in the Fe3+ state (Perls’ stain;Figure 3A), and lower levels of Fe2+ 
(Turnbull’s stain). Inclusionswere positive for ferritin although some of the largest were unstained 
(Figure 3B), with ferritin staining also present in neuronal and some glial nuclei. Iron-positive 
inclusions were variably positive for ubiquitin (Figure 3C), andeither free in the neuropil or cell 
associated and involved cells with the morphology ofmicroglia, astrocytes, or oligodendrocytes 
(Figure 3E, F). Many inclusions showed immunocytochemical profiles which may suggesta 
neuronal origin (e.g. neurofilament (Figure 3H), and ubiquitin) and were argyrophilic (Gallyas 
silver).
Iron staining showed a rim of iron rich glial cells and inclusions surrounding the basal ganglia that 
was prominent in most cases (e.g. Supplementary Figure 2), a feature seen in MRI imaging (24). 
Adjacent to the cystic lesions, reactive GFAP positiveastrogliosis and reactive HLA-DR/DP/DQ A
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immunopositivemicroglia-like cellswere present(Supplementary Figure 3). Cells with a 
morphology similar to oligodendrocytes in the remaining laminae of the globus pallidus and 
putamen showed iron and ferritin positive intracytoplasmic inclusions (SupplementaryFigure 4). 
Small rounded cells, often appearing as a linear arrangement of cells, and with the appearance of 
oligodendrocytes, were observed in deep white matter tracts and showed extensive 
intracytoplasmic iron, accompanied by ubiquitin positive axonal profiles and spheroids. 
Neuronal loss was evident in the globus pallidus in III-VI, butnot evident in case I despite iron 
deposition (Figure4A, B) and gliosis, and mild in case II, with in cases IV-VI very few pallidal 
neurones remaining due to cavitation. Large neurons in the putamen were readily evident in case I 
(Figure4G), diminished in case II, and virtually absent in cases III-VI.  In all cases,some small 
putaminal neuronswere still apparentnear the cavity. Nuclear neuronalferritin or iron staining and 
a background cytoplasmic staining with granular cytoplasmic iron-positive profileswere observed 
in the remaining globus pallidus (Figure 4A-E). Neuronswere observedsurrounded by iron reactive 
inclusions suggesting accumulation of iron and ferritin in degenerated satellite glia (Figure4F). In 
areas of the putamen in case I, large neurons could be observed filled with iron. Many of the larger 
iron inclusions in the neuropil had a form suggesting a neuronal origin. The neurons of the nucleus 
basalis of Meynertwere preserved in all cases despite iron-positive inclusions throughout the 
neuropil. In cases III, Vand VI, phospho-Tau (AT8) and scattered alpha-synuclein (KM51) 
positive neurites were observed in the neuropil (SupplementaryFigure5).
Midbrain and Brainstem
The substantia nigra showed minimal pigmented neuron loss in cases I and II but extracellular 
neuromelanin in cases III-VI. In the pars reticulata, non-pigmented neurons were present and 
showed ferritin and accompanying iron deposition, along with scattered iron and ferritin positive 
inclusions and iron-containing glia with a morphology similar tooligodendrocytes and microglia. 
Immunostaining for phospho-Tau(AT8) was negativewith the exception of case V which showed 
scattered neuritic staining. Alpha-synuclein staining demonstrated rare positive neurites in cases 
II, III, V, and VI within the pars compactaand rare Lewy bodies in case VI (SupplementaryFigure 
5). The subthalamic nucleus and the red nucleus showed changes similar to those in the globus 
pallidus and putamen but in a less advanced state. Only mild changes were present in the thalamus 
including iron and ferritin inclusionswith no evidence of major degenerative changes.  A
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Iron and ferritin deposition were minimal or absent in the pons and medulla and the pyramidal 
tracts appeared normal. Scattered AT8 positive neurites were seen in the dorsal motor nucleus of 
the vagal nervein cases V and VI. Scattered α-synuclein positive neurites in the dorsal motor 
nucleus, medullary reticular formation, and locus coeruleuswere seen in cases V and VI.
Cerebellum
The cerebellar dentate nucleus showed neuronal loss in case II, which was extensive in cases III-
VI, with surrounding demyelination. There was prominent iron and ferritin deposition both within 
and as a rim surrounding the nucleus (SupplementaryFigure 6B) predominantly inGFAP-positive 
astrocyte-like and HLA-DR/DP/DQ or CD68-positive microglia-like cells.Ubiquitinated profiles 
were also present within the dentate nucleus. Oligodendrocyte-like cells and to a lesser extent cells 
with a morphology similar tomicroglia were observed in various stages of iron and ferritin loading 
from small dust like intracytoplasmic inclusions, to large accumulations that almost obliterated the 
cell. Similar changes were seen in white matter cells with features suggestive ofoligodendrocytes 
(Supplementary Figure 6C). Changes in the cerebellar cortex were mild and consisted of iron 
positive cells with a Bergmann glia-like phenotype (Supplementary Figure 6E, F) and intranuclear 
Purkinje cell ferritin and iron staining (Supplementary Figure 6D) with mild Purkinje cell loss in 
cases III-VI.
Cerebral Cortex and White Matter   
Within the cerebral cortex, iron and ferritin-positive microglia-like and oligodendrocyte-like 
cellular profiles were present throughout the cortical grey, particularly in a perineuronal location, 
these being notable in the hippocampal subiculum (Supplementary Figure 7E). Iron and ferritin 
positive oligodendrocyte-like cellsoccurred throughout the white matter. Major neuronal loss in 
neocortical or archicortical grey matter, including the hippocampus was not evident 
(SupplementaryFigure 7). CasesV and VI showed AT8 positive phospho-Tau positive neurites in 
the hippocampus, entorhinal cortex and amygdala (Braak stage II/III; Supplementary Figure 5E,F). 
The superficial and deep white matter tracts showed ubiquitin positive axonal profilesparticularly 
in cases III, V, and VI.
Metal levels in HFA
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We determined levels of several metals in cases (II, III, and VI) of HF where frozen tissue was 
available using ICPMS (Table 1). Levels of iron in the globus pallidus tissue were slightly but not 
significantly elevated. In the putamen, iron levels were slightly reduced compared to controls. Iron 
levels were significantly increased infrontal cortex and thalamus in HFcompared to controls, but 
not in motor cortex or cerebellum. In general copper levels were reduced in several regions in HF, 
and this was significant in the putamen, motor cortex and thalamus. Manganese and zinc levels 
were generally unchanged or only slightly reduced in HF. 
Ferritin alterations in HF
In the frontal cortex, we observed a trend towards anincrease of FTL levels (P=0.08), a significant 
increase in total ferritin levels (P<0.01) and a significantly altered FTH/FTL ratio in HF(P<0.01; 
Figure 5).Analysis of native ferritin complex in controls revealed the presence of one band of 480 
kDa, corresponding to the 24-mer ferritin complexin control frontal cortex (Figure 5). In HFfrontal 
cortex and cerebellum however,we detected ferritin oligomers of approximate molecular weight 
720 and 1000 kDa, that were immunopositive for FTL and FTH. This observation made us explore 
further the solubility of ferritin. Frontal cortex and cerebellum samples were fractionated 
(Supplementary Figure 8) and analysed by SDS-PAGE. High molecular weight protein species, 
immunopositive for FTL, were detected in all fractions of HFbrain preparations, including 88% 
and 98% formic acid fractions (Figure 6). Theseferritin oligomers in the formic acid fractions 
represent aggregated forms of ferritin, most likely stabilised by covalent bonds, as they were 
resistant to formic acid and TCEP-HCl. Monomeric FTL and FTH subunits were also present in 
the control brain formic acid preparations, suggestive of age-related haemosiderin accumulation 
and that ferritin,given its homopolymeric nature,can aggregate spontaneously. Due to the presence 
of aggregated protein and the presence of ubiquitin in inclusions we sought to determine if ferritin 
itself is ubiquitinated and particularly since polyubiquitination via the K48-linkage is known to 
target proteins for proteasomal degradation and ferritin monomers can undergo proteasomal 
degradation(26, 27). We immunoprecipitated ferritin from the frontal cortex and cerebellum and 
probed for polyubiquitination using SDS-PAGE and immunoblotting. We detected two bands of 
polyubiquitinated FTL, a fainter band migrating at approximately 27 kDa and a major band at 
approximately 55kDa potentially representing a dimer, in both HFand controls (Figure7). These 
polyubiquitinated bands were readily observed in soluble extracts of total brain protein in HF and 
to a lesser extent in control tissue (Supplementary Figure 9). Interestingly, the degree of A
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polyubiquitination in Urea soluble tissue extracts in HFseemed to be lower than in controls, in 
particular in a sample showing the highest levels of detergent resistant ferritin oligomers. This 
observation may indicate failed clearance of ferritin in HF, possibly due to misfolding and 
aggregation, which may partially account for the accumulation of ferritin seen in HF. 
Iron transport protein levels are not affected in HF
Due to the elevated iron and ferritin in HF, we determined if iron entry into the brain is regulated 
by determining expression of iron import proteins, ferroportin 1 and transferrin receptor 1. There 
were no significant changes in ferroportin 1 or transferrin receptor 1 protein levels (Supplementary 
Figure10).
Altered mitochondrial iron metabolism in HF
Since iron within the brain is predominantly used for oxidative metabolism in mitochondria, the 
handling and use of iron was determined within HFpatient brain samples. In HF frontal cortex, 
levels of mitochondrial proteins were unaltered with levels of the major mitochondrial protein 
VDAC1/porin,frataxin, NDUFB8, ubiquinol- cytochrome c reductase core protein 1, MTCO2 and 
ATP5Aunchanged (not shown). NDUFS1 was however significantly decreasedin frontal cortex of 
HF, by 15% compared to controls (P = 0.0223) (SupplementaryFigure 11).Mitochondrial DNA 
(mtDNA) from HF (frontal cortex, globus pallidus, thalamus, cerebellum, putamen and motor 
cortex)showed no significant differences in the copy number(Supplementary Figure12), or the 
presence of major deletions in any brain areas compared to controls. Next generation sequencing 
also did not reveal a higher mutational burden in the severely affected globus pallidus compared to 
the relatively spared cerebellum (Supplementary Figure 13 and Supplementary Table 4).
No major evidence of oxidative stress in HF
As iron has been linkedto reactive oxygen species generation, we explored oxidative stress 
markers in HF brains. Immunohistochemical analysis of haem oxygenase 1 in multiple brain 
regions did not show a statistically significant difference in levels inHF compared to aged controls 
(Supplementary Figure 14 and Supplementary Table 5).Analysis of protein carbonylgroups, 
markers of protein oxidative changes, in frontal cortex did not reveal any significantchangesin HF 
(Supplementary Figure15). Similarly, we saw only a small elevation in SOD1 expression but no 
change in SOD2 or HSP70 (Supplementary Figure 15).A
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Lysosomal functions in neuroferritinopathy
As ferritincan be degraded by lysosomes(28-32)we explored lysosomal dysfunction as 
contributing toaccumulation of ferritin and ferritin oligomers.Cathepsin D and E enzyme activities 
showed nosignificant change in HF (SupplementaryFigure 16). Lysosomal markers, LAMP1, 
LAMP2, and TFEB (Transcription Factor EB) also showed no significant differences, however 
Cathepsin Dwas significantly reduced in HF(P = 0.003) (SupplementaryFigure 16).
Discussion
This study significantly advances our understanding of the neuropathology of hereditary 
ferritinopathy/neuroferritinopathy, highlighting unique pathological features of the disorder 
andsuggesting potential novel mechanismsof neurodegeneration.
Intriguingly when measuring tissue iron content, we observed largely similar overall iron levels in 
HF cases compared to controls within several brain regions including the putamen and globus 
pallidus (Table 1). Whilst this may be mediated by cavitation, and therefore the loss of cellular 
iron in these regions to CSF, the observation ofgenerally reduced copper, zinc, and manganese 
particularly within the putamen, and nodown-regulation of iron transport mechanismssuggests that 
accumulation of iron does not necessarily mediate neurodegeneration in the FTL 460InsA 
mutation. Rather,local cell specificchanges potentially due toFTL accumulation (see below) may 
underlie these effects through loss of cells manifesting as reduced levels of other metals including 
copper. The mechanism underlying the dysregulation of additional metals, particularly in the 
putamen, has not been observed in other forms of NBIA. Similar changes in metalshave been 
observed in the heart in Friedreich’s ataxia(33), and therefore a comparable process may occur in 
other degenerative disorders associated with iron. Understanding the relative contribution of iron 
and other metals to diseasepathogenesis may have significant implications for treatment, including 
the use of chelation agents being currently trialled for other NBIA disorders.
Histopathological assessment of HF cases showed that excess iron staining within cells in HF 
closely paralleled normal age-associated iron deposition(17), though potentially to pathological 
excess within individual cells. In HF areas such as the globus pallidus, substantia nigra pars 
reticulata, and cerebellar dentate show high intracellular iron staining with the predominant A
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accumulation of ironwithin glial cells, with their morphology and immunophenotype suggestive of  
oligodendrocytes and microglia(1, 2). Both cell types in the normal brain are known to contain 
FTL as themajor form of ferritin(1, 34) suggesting that the same relative distribution of iron occurs 
within HF as in the aging brain at the cellular level,with the deviation from normal levels most 
likely mediated by altered function of mutant FTL. High resolution imaging, perhaps using 
electron microscopy, should however be used to definitively determine that nature of these 
inclusions involves both ferritin and iron, and how these inclusions affect the morphology and 
potential function of cells.It is of interest that in the case of individuals with the FTL460InsA 
mutation they show dystonia and choreiform movement disorders as the presenting phenotype 
although cerebellar pathology is readily evident (22, 24, 25). In other cases of HF with different 
mutations, cerebellar features are prominent or the mutation shows either cerebellar or 
Parkinsonian features (11, 35).   
We observed cells with a morphology similar tooligodendrocytes at various stages of iron and 
ferritin loading, ranging from small cytoplasmic iron and ferritin deposits that gradually appear to 
coalesce into larger clusters of FTL and iron. Critically, we observed oligodendrocyte-like cell 
deathas a result of this process within key anatomical regions such as the internal medullary 
laminae between the globus pallidus and putamen, and this islikely to lead to the observed 
cavitation exhibited as a core feature of HF, in part causing deafferentation. Ongoing cell death in 
this region and throughout the basal ganglia could result in a self-perpetuating cycle ofmutant 
ferritin production, iron loading and consequent ferritin aggregation, iron release from dead and 
dying cells and cellular iron uptakeinto adjacent cells into an abnormal ferritin. The observed rim 
of mutant FTL and iron containing GFAP-positive astrocyte like cells and HLA-DR/DP/DQ-
positive and CD68-positive microglia-like cells surrounding the basal ganglia and dentate nucleus 
is consistent with this. Itis therefore highly likely to explain the marked cavitation observed in 
HFwhich significantly advances our understanding of this ubiquitous feature (36). 
Whilst our observations associate neuropathology and cell death with gliain particular regions, we 
also tested additional possible mechanisms.Previous studies using in vitroand in vivomodels have 
suggested that neuronal dysfunction may occur because of ROSmediated through acquired 
mitochondrial dysfunction(37, 38). However,we observed no significant evidence of elevated ROS 
when testing for oxidative stress markersusing a cellular histochemical approach, no evidence of A
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secondary mitochondrial DNA mutations, nomajor changes in mitochondrial mass, and no 
differences in almost all OXPHOS proteins to indicate mitochondrial dysfunction. These data 
provide compelling evidence to suggest that ROS and mitochondrial dysfunction are unlikely to be 
key mediators of neurodegeneration in HF challenging previous hypotheses(37-39). They also 
challenge the idea that oxidative stress due to iron may lead to common neurodegenerative 
disorders. The HF patients studied here showed little neurodegenerative pathology in the form of 
NFT or Lewy bodies, although Case II and VI did exhibit very occasional Lewy bodies in the 
medulla and substantia nigra, and in cases II, V, and VI, hyperphosphorylated tau accumulation 
was present, but at levels similar to found in normal older persons. Furthermore, whilst 
overexpression of mutant FTL leads to oxidative stress in cell and animal models(40, 41), similar 
levels of oxidative stress are not generated in HF.  Therefore, modelling HF in cell linesor mice by 
overexpression, may not reliably recapitulate the cell-type and region-specific vulnerability 
exhibited in patients.
The observation of ferritin protein and also ironlocated in the nucleusparticularly in neurons but 
also notably liver hepatocytes, was reminiscent of nuclear protein accumulationseenin CAG repeat 
disorders such as Huntington’s disease and dentatopallidorubroluysian atrophy (42, 43). To the 
best of our knowledge protein aggregates have not previously been biochemically observed in 
HFbrain tissue due to the FTL 460InsA mutation, althoughthe presence of FTL and FTH 
monomers and dimers has been shown in putaminal and cerebellar inclusion bodies from a case 
with the 498-499InsTC in exon 4 of FTL(11). Certainly, ferritin can localise to the nucleus in some 
cells and tissues although this is typically FTH and not FTL(44-47). However, we identified large 
oligomers of FTL that are resistant to formic acid, appear to be covalently bonded and 
ubiquitinated. FTL aggregates were notnoticeable in controls, and the presence of the FTL 
mutation in a region of the protein which is important in the folding of the peptide (37, 48) 
suggests that this aggregate is likely to be highly HF specific and may be an exaggerated version 
of the intrinsic ability of FTL monomers to self-assemble (49). This aggregation may also lead to 
some proteasomal inhibition by mutant FTL since excess FTL can accumulate within lysosomes 
(49) and mutant FTL can reduce proteasomal metabolism (37).Identification of aggregated 
ubiquitinated ferritin suggests that the gradual accumulation of iron in the nucleus may be 
secondary to the nuclear aggregation of FTL, which is impaired in its ability to accumulate iron 
(37).  In addition, the lack of association between axonal iron deposition and axonal ubiquitination A
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was also striking. Thismay suggest that iron deposition may not primarily drive neuronal 
dysfunction in some brain regions, and instead may be driven by ferritin aggregation, supportive 
of the previously proposed model of ferritin aggregation and toxic gain of function (50), and 
similar to other neuronal aggregates such as Lewy bodies in PD or Tau in FTD (51), though 
further work is required to prove this association.
Finally, thefinding of widespread neuronal dystrophy and lack of association between neuronal 
ubiquitination and iron, irrespective of aetiology,also conclusivelysuggests that HFis not simply a 
focal iron accumulation disorder involving the CNS, particularly given hepatic pathology observed 
herein and peripheral organ ferritin inclusion bodies reported elsewhere (11).HF should be 
described therefore asa diffuse neurodegenerative disorder despite the ostensibly focal changes 
observed on radiological imaging and macroscopic neuropathological examination. Such diffuse 
findings may also help explain some of the cognitive features observed in the disorder that cannot 
be entirely explained by focal pathology (24, 52).
In summary, we find that the predominant clinical phenotypic features of HFare likely to arise 
fromloss of integrity of the internal medullary lamina of the globus pallidus, leading to destruction 
of the basal ganglia. This pathology follows an exaggerated form of the normal age-associated 
accumulation of iron and ferritin in the brain. The underlying mechanism in HF may not however 
be duesolely to iron mediated oxidative stress, but aggregation of mutant FTL, ubiquitination and 
inhibition of proteostasis leading to cell death in common with several other neurodegenerative 
disorders.
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Figures and Tables Legends
Figure 1. Peripheral pathology in Hereditary Ferritinopathy.
Liver tissue shows the presence of widespread intracellular inclusions containing iron (A; Perls’ 
Neutral Red x 40 magnification) and Ferritin L-chain (B; x 40 magnification) typically within cell 
nuclei. Ventricular myocytes demonstrate intranuclear ferritin staining (C; x 10 magnification, D; 
x 40 magnification) although iron staining is not apparent (not shown).(E) Skin section showing 
presence of intranuclear FTL staining and diffuse staining of dermis (x 20 magnification).
Figure 2. Macroscopic pathology in HF.
(A) MRI image of an individual with HF in an advanced stage with cavitation of the basal ganglia 
and decreased signal intensity in thalamus and lower layers of the cerebral cortex. Coronal 
sections of fixed brain tissue: (B) In case III there are cystic cavities in the globus pallidus (broad 
vertical arrow) and within the putamen (narrow vertical arrow), with sparing of the caudate 
nucleus (horizontal arrow). The cerebral cortex shows discoloration in the lower layers at the 
border with white matter. (C) Midbrain from Case III showing normal melanisation but with 
diffuse brown discoloration of the substantia nigra pars compacta and pars reticulata, along with 
cerebral peduncles (horizontal arrow). There is some discoloration of the medial geniculate body 
(vertical arrow). (D) Cerebellum from Case III showing the dentate nucleus with brown 
discoloration and possible cavitation (arrow). The cerebellar cortex appears normal.
Figure 3. Microscopic pathology of basal ganglia in HF.
(A) Border of the globus pallidus cyst showing granular iron/ferritin bodies stained heavily for 
iron (Perls’ method with DAB intensification; Case VI). (B) Ferritin content of the iron/ferritin 
bodies (FTL IHC) which are (C) only weakly reactive to ubiquitin (IHC for ubiquitin). (D) Section 
through the anterior globus pallidus showing surviving large neurons at an early disease stage 
(CFV; case I). (E) Case I showing roughly spherical iron ferritin bodies of varying size in the 
cytoplasm and in cellular processes of cells with the morphology ofmicroglia and 
oligodendrocytes, and also free in the neuropil (FTL IHC). (F) Iron content within glial cells, 
showing the presence of iron within glial processes (Perls’ method). (G) Abundant eosinophilic 
profiles, corresponding to the iron/ferritin bodies, in the basal ganglia region that also stain for (H) 
neurofilament along with axonal profiles. (Scale Bars: A, B, C, G, H =300 m; D, E, F =100 m).A
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Figure 4. Neuronal iron staining in the basal ganglia.
(A) Medial globus pallidus from case I showing iron stained neurons. Neurons show variable iron 
reactivity:  (B) diffuse cytoplasmic staining with strong nuclear staining; (C) fine granular 
cytoplasmic staining; (D) increased cytoplasmic iron content; (E) iron/ferritin bodies possibly 
derived from degeneration of overloaded neurons (arrows). (F) Iron-containing neurons are 
surrounded by iron/ferritin bodies which may represent remnant satellite glial cells. (G) Neurons 
in the lateral putamen show normal neuronal morphology with absent iron staining despite the 
presence of iron/ferritin bodies within the neuropil.  (H) In contrast, the medial putamen adjacent 
to the cystic cavity shows iron-stained neurons with iron extending out into dendritic processes 
(Perls’ method with DAB intensification). (Scale Bars: A=100 m; D, E, G, H=50 m; B, C=25 
m).
Figure 5. Analysis of ferritin in Hereditary Ferritinopathy/Neuroferritinopathy and controls.
Samples of frontal cortex tissue were analysed using western blotting and probed using ferritin 
specific antibodies (A). Trend towards increased levels of both FTL (B) and FTH (C) were seen in 
HF (NF) in comparison to control tissue samples, with an altered FTH/FTL ratio (**, p<0.01, 
unpaired t-test) (D). Native PAGE analysis of the ferritin complex (E) to identify the ferritin 
holoprotein demonstrated the presence of two to three bands migrating at 480 kDa, 720 kDa and 
approximately 1000 kDa in HF (NF) and only one band showing the ferritin holoprotein monomer 
in controls when probed with antibodies recognising both FTL and FTH. For comparison, western 
blot analysis shows levels of ferritin in the same cases (F, G). Native PAGE and immunoblotting 
using antibodies specific to FTL (H) and FTH (I) confirmed the presence of ferritin oligomers in 
the patients. 1, 2, etc. – patient and control frontal cortex; 3* - Cerebellum.
Figure 6. Solubility of ferritin in HF.
Tissue samples were sequentially fractionated based on protein solubility properties and analysed 
by SDS PAGE and immunoblotting using anti-FTL and anti-FTH antibodies. GAPDH was used as 
a loading control when suitable. Oligomers of FTL are seen in all fractions of HF brain extracts. 
The presence of higher molecular weight species of FTL in the formic acid purified fractions 
suggests the formation of covalent bonds between FTL molecules. Age matched controls were not 
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free from the detergent resistant and formic acid soluble ferritin possibly due to the presence of 
haemosiderin, however the formation of oligomers was generally reduced compared to HF. 
Figure 7. K48-linkage polyubiquitination of ferritin in HF and controls.
Immunoprecipitation of ferritin from tissue extracts with western blot analysis indicated K48 
polyubiquitination (arrowheads) of ferritin monomer and higher molecular weight (57kDa) ferritin 
K48 ubiquitin linkage. Use of FTL antibody showed monomeric ferritin light chain (panel B, 
~22kDa, lower arrow) and in HF potential FTL dimers (~44kDa, upper arrow). Extended exposure 
times for blots using both FTL and K48 polyubiquitin antibodies showed K48-ubiquitinated FTL 
monomers and dimers in bothHF and control frontal cortex.
Table 1. Metal levels in HF.
Snap frozen unfixed tissue samples were wet digested in nitric acid and metals determined using a 
standard additions method with inductively coupled plasma emission mass spectrometry (ICPMS). 
Metal levels are presented as ng metal/mg wet weight of tissue with control samples (Age 68.2yrs 
± 4.8 yrs [SD] range 63-74; 2F/4M) and HF cases (Age 61.3yrs ± 6.5 yrs [SD] range 55-64; 3F). 
Comparisons were made with unpaired Mann-Whitney U-test assuming unequal variances and 
uncorrected. *, P values <0.05.
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Table 1:Metal levels in hereditary ferritinopathy. 
Globus Pallidus Putamen Frontal Cortex Motor Cortex Thalamus Cerebellum
56Fe Control
HF
246692 ± 73230
664227 ± 798814
171962 ± 30068
170011 ± 61764
50912±16441
76647 ± 11157**
67418±11619
113525 ± 44973
73476 ±20912
122186 ± 23807*
47590 ± 15674
58636 ± 6128
55Mn Control
HF
 592 ± 60 
1858 ± 2622
597 ± 56
442 ± 46***
217±54
243 ± 55
239±34
276 ± 74
463 ± 104
439 ±112
323 ± 44
351 ± 21
63Cu Control
HF
 7172 ± 771
15465 ± 20550
8151 ± 1724 
3519 ± 968***
4019 ± 1503
2875 ± 445
4716 ± 564
3222 ± 457***
5629 ± 1298
2841 ± 688***
5469 ± 1005
3892 ± 920
66Zn Control
HF
14440 ± 1491
35752 ± 48688
15915 ± 1532 
11225 ± 96***
13020 ± 3899
12888 ± 1624
12997 ± 1369
12295 ± 1224
14497 ±2065
13477 ± 2199
12875 ± 1286
14326 ± 850
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